INDEX

VOLUME 23 1968

A

Address by His Holiness Paul VI to Representatives of the Food Standards Commission. Mar., p. 162.

Administrative Procedure

Separation of Functions in FDA Administrative Proceedings. Mar., p. 132.

Some Common and Uncommon Hearing Procedures Under the Federal Food, Drug and Cosmetic Act. Sept., p. 457.

Some Suggestions for Improvements in the Hearing and Rulemaking Procedures of the Food and Drug Administration. Sept., p. 465.

The Food and Drug Administration's View on Procedural Rules. Oct., p. 481.

Administrative Rulemaking

Fair Hearing in Administrative Rulemaking. July, p. 366.

General Principles of Administrative Rulemaking Under the Federal Food, Drug and Cosmetic Act. Oct., p. 476.

Some Suggestions for Improvements in the Hearing and Rulemaking Procedures of the Food and Drug Administration. Sept., p. 465.

The GMP Regulations and the Proper Scope of FDA Rulemaking Authority. Nov., p. 532.

Adulteration

A Neighbor Comments Upon Some National and International Aspects of Food and Drug Legislation. Jan., p. 36.

Latin-American Food Code. Aug., p. 396.

Voluntary Compliance Encouraged by Bureau Changes. Apr., p. 227.

Advertising

Drug Advertising Regulations. Jan., p. 21.

Prescription-Drug Advertising — Blight or Light? May, p. 242.

Question and Answer Panel of the FDLI-FDA Eleventh Annual Educational Conference. Apr., p. 185.

The Prescription Drug Advertising and Labeling Regulations. Jan., p. 12.

Alimentary Pastes (pastas)

Latin-American Food Code—Chapter IX. Nov., p. 550.

B

Bakery Products

Latin-American Food Code—Chapter IX. Nov., p. 550.

Ballard, R. W.—Risks v. Benefits in Drug Development. Jan., p. 25.

Banes, Daniel—International Drug Pharmacopeia. June, p. 322.

Barnard, Alfred

Need for Formal Guidelines in the Food Industry (The). Jan., p. 4.

Regulator and the Regulated (The). Dec., p. 628.

Brennan, Bruce J.—The Right to Self-Medication—A Continuing Conflict Between Congressional and Agency Policy. Oct., p. 487.

Building Tomorrow's System. Aug., p. 432.

Byerley, Walter E.—Some Common and Uncommon Hearing Procedures Under the Federal Food, Drug and Cosmetic Act. Sept., p. 457.

Byers, Theodore E.—Sampling and Testing of Drugs. Apr., p. 200.

C

Canada
A Neighbor Comments Upon Some National and International Aspects of Food and Drug Legislation. Jan., p. 36.

Cancer
Risks v. Benefits in Cancer Drug Development. Jan., p. 29.

Cannan, R. Keith—Status of the Drug Efficacy Study of the National Academy of Sciences-National Research Council. Jan., p. 32.

Cassidy, Frederick A.—The Federal Trade Commission and the Fair Packaging and Labeling Act. June, p. 312.

Central America
Food and Drug Legislation in Central America and Panama. May, p. 253.

Cereal Preparations
Latin-American Food Code—Chapter IX. Nov., p. 550.

Cereals
Latin-American Food Code—Chapter IX. Nov., p. 550.

Chapman, D. G.—A Neighbor Comments Upon Some National and International Aspects of Food and Drug Legislation. Jan., p. 36.

Codex Alimentarius Commission
Addressed by His Holiness Paul VI. Mar., p. 162.
Report of the Fifth Session of the Joint FAO/WHO Codex Alimentarius Commission. May, p. 271.

Condon, William J.—Product Liability—1967. Mar., p. 114.

Consumer Laws
Federal Pre-emption in Consumer Laws. Feb., p. 79.

Consumer Protection
The Future of Consumer Protection. Dec., p. 608.

Cooperation
Industry and Government Cooperation—A Two-way Street. Sept., p. 444.

Counsel's Role in Current Good Manufacturing Practice. Feb., p. 71.

Current Good Manufacturing Practices Compliance—A Review of the Problems and an Approach to Their Management. Dec., p. 580.

Current Tidings and Trends in Drug Appraisal. Jan., p. 42.

D

Delmore, Fred J.—Voluntary Compliance Encouraged by Bureau Changes. Apr., p. 227.

Depew, Franklin M.
Introductory Statement. Feb., p. 69.
Report of the Fifth Session of the Joint FAO/WHO Codex Alimentarius Commission. May, p. 271.
Salmonellae—A Current Challenge (The). Mar., p. 164.

Developments at FDA. Mar., p. 126.

Devices
Some Applications of Drug, Device and Narcotic Laws for Health Science Practitioners. Feb., p. 89.
Surgical Implants: Drugs or Devices, and New Device Legislation. Oct., p. 510.

Drug Advertising Regulations. Jan., p. 21.

Drug Compendiums
Building Tomorrow's System. Aug., p. 432.
International Drug Pharmacopeia. June, p. 322.

Drug Development
Building Tomorrow's System. Aug., p. 432.
Risks v. Benefits. Jan., p. 25.
Risks v. Benefits in Cancer Drug Development. Jan., p. 29.

Drug Efficacy

Building Tomorrow's System. Aug., p. 432.

Status of the Drug Efficacy Study of the National Academy of Sciences-National Research Council. Jan., p. 32.

Drug Legislation

Ethical and Legal Implications of Drug Substitution. June, p. 284.

In Canada. Jan., p. 36.

In Central America and Panama. May, p. 253.

Legal Control of Narcotics. June, p. 306.

The EEC on the Way to a Common Market for Drugs: Its Meaning for Foreign Imports. Oct., p. 500.

Some Applications of Drug, Device and Narcotic Laws of Health Science Practitioners. Feb., p. 89.

Surgical Implants: Drugs or Devices, and New Device Legislation. Oct., p. 510.

Survey of Current Legal Problems in the Drug Area. Sept., p. 449.

Drugs

A View from the Top—The Pharmaceutical Manufacturer's Multi-Responsibilities. Apr., p. 203.

Question and Answer Panel of the FDLI-FDA Eleventh Annual Educational Conference. Apr., p. 185.

Sampling and Testing of Drugs. Jan., p. 8.

Sampling and Testing of Drugs. Apr., p. 200.

Surgical Implants: Drugs or Devices, and New Device Legislation. Oct., p. 510.

The EEC on the Way to a Common Market for Drugs: Its Meaning for Foreign Imports. Oct., p. 500.

The Right to Self-Medication—A Continuing Conflict Between Congressional and Agency Policy. Oct., p. 487.

E

Edelman, Sidney—Search Warrants and Sanitation Inspections—The New Look in Enforcement. Feb., p. 52.

EEC on the Way to a Common Market for Drugs: Its Meaning for Foreign Imports (The). Oct., p. 500.

Endicott, Kenneth M.—Risks v. Benefits in Cancer Drug Development. Jan., p. 29.

Ethical and Legal Implications of Drug Substitution. June, p. 284.

European Economic Community

International Drug Pharmacopeia. June, p. 322.

The EEC on the Way to a Common Market for Drugs: Its Meaning for Foreign Imports. Oct., p. 500.

F

FDA Program for 1969 (The). Dec., p. 621.

FDA Self-Certification Program (The). May, p. 236.

FDA Today and Tomorrow. Dec., p. 614.

Fair Hearing in Administrative Rulemaking. July, p. 366.

Fair Packaging and Labeling Act—The Problems and Effects of Discretionary Regulations (The). Mar., p. 109.

Fair Packaging and Labeling Act of 1967

A Reasoned Approach to Regulation Based on Toxicologic Considerations. May, p. 260.

Fair Packaging and Labeling Act—The Problems and Effects of Discretionary Regulations. Mar., p. 109.

The Federal Trade Commission and the Fair Packaging and Labeling Act. June, p. 312.

The Prescription-Drug Advertising and Labeling Regulations. Jan., p. 12.

Federal Food, Drug and Cosmetic Act

Fair Hearing in Administrative Rulemaking. July, p. 366.

General Principles of Administrative Rulemaking Under the Federal Food, Drug and Cosmetic Act.

Federal Food, Drug and Cosmetic Act —continued
Some Common and Uncommon Hearing Procedures Under the Federal Food, Drug and Cosmetic Act. Sept., p. 457.

Federal Pre-emption in Consumer Laws Feb., p. 79.

Federal Trade Commission
Authority to issue discretionary regulations. Mar., p. 109.
Philosophy on the right to purchase over-the-counter drugs. Oct., p. 494.
The Federal Trade Commission and the Fair Packaging and Labeling Act. June, p. 312.

Federal Trade Commission and the Fair Packaging and Labeling Act. June, p. 312.

Fisture, Charles M.—Legal Aspects of Modified and Vegetable Fat Dairy Products. Apr., p. 209.

Food Additives
A Reasoned Approach to Regulation Based on Toxicologic Considerations. May, p. 260.
Latin-American Food Code. Aug., p. 396.
Latin-American Food Code. Nov., p. 550.
Petitions to establish safety. Sept., p. 462.

Food and Drug Administration
Developments at FDA. Mar., p. 126.
Have the FDA Hearing Regulations Failed Us? Nov., p. 524.
Philosophy affecting voluntary compliance. Apr., p. 227.
Question and Answer Panel of the FDLI-FDA Eleventh Annual Educational Conference. Apr., p. 185.
Question and Answer Panel of the FDLI-FDA Eleventh Annual Educational Conference. July, p. 332.
Question and Answer Panel of the FDLI-FDA Eleventh Annual Educational Conference—Afternoon Session: Foods Workshop. July, p. 348.
Separation of Functions in FDA Administrative Proceedings. Mar., p. 132.
Some Suggestions for Improvements in the Hearing and Rulemaking Procedures of the Food and Drug Administration. Sept., p. 465.
The FDA Self-Certification Program. May, p. 236.
The Food and Drug Administration's View on Procedural Rules. Oct., p. 481.

Food and Drug Administration's View on Procedural Rules (The). Oct., p. 481.

Food and Drug Legislation in Central America and Panama. May, p. 253.

Food Legislation
In Canada. Jan., p. 36.
In Central America and Panama. May, p. 253.
Latin-American Food Code—Chapter IX. Nov., p. 550.
Latin-American Food Code—Chapter XI. Aug., p. 396.

Forte, Wesley E.
Fair Hearing in Administrative Rulemaking. July, p. 366.
Fair Packaging and Labeling Act—The Problems and Effects of Discretionary Regulations (The). Mar., p. 109.
GMP Regulations and the Proper Scope of FDA Rulemaking Authority (The). Nov., p. 532.
General Principles of Administrative Rulemaking Under the Federal Food, Drug and Cosmetic Act. Oct., p. 476.

Frawley, John P.—A Reasoned Approach to Regulation Based on Toxicological Considerations. May, p. 260.

Fruits
Latin-American Food Code—Chapter XI. Aug., p. 396.

Future of Consumer Protection (The). Dec., p. 608.

Fundamental Principles and Objectives of a Comparative Food Law: Volume 2 (Review of) Dec., p. 632.

G

GMP Regulations and the Proper Scope of FDA Rulemaking Authority. Nov., p. 550.

General Principles of Administrative Rulemaking Under the Federal Food, Drug and Cosmetic Act. Oct., p. 476.

Generic Name

A View from the Top—The Pharmaceutical Manufacturer's Multi-Responsibilities. Apr., p. 203.

Ethical and Legal Implications of Drug Substitution. June, p. 284.

FDA Today and Tomorrow. Dec., p. 614.

Goddard, James L.—Building Tomorrow's System. Aug., p. 432.

Golle, H. A.—The FDA Self-Certification Program. May, p. 236.

Good Manufacturing Practice Regulations

Counsel's Role in Current Good Manufacturing Practice. Feb., p. 71.

Current Good Manufacturing Practices Compliance—A Review of the Problems and an Approach to Their Management. Dec., p. 580.

The GMP Regulations and the Proper Scope of FDA Rulemaking. Nov., p. 532.

The Need for Formal GMP Guidelines in the Food Industry. Jan., p. 4.

Goodrich, William W.—The Food and Drug Administration's View on Procedural Rules. Oct., p. 481.

H

Hauser, Julius—Drug Advertising Regulations. Jan., p. 21.

Have the FDA Hearing Regulations Failed Us? Nov., p. 524.

Hazardous Substances

A Reasoned Approach to Regulation Based on Toxicologic Considerations. May, p. 260.

FDA Today and Tomorrow. Dec., p. 614.

Forms used for inspection. Feb., pp. 63-68.

Laws of the several states governing the use of pesticides. Mar., pp. 157-161.

Question and Answer Panel of the FDLI-FDA Eleventh Annual Educational Conference. July, p. 332.

Hoffman, Joel E.—Some Suggestions for Improvements in the Hearing and Rulemaking Procedures of the Food and Drug Administration. Sept., p. 445.

I

Industry and Government Cooperation—A Two-way Street. Sept., p. 444.

International Drug Pharmacopeia. June, p. 322.

Introductory Statement. Feb., p. 69.

J

Jeffries, Seymour B.—Current Good Manufacturing Practices—A Review of the Problems and an Approach to Their Management. Dec., p. 580.

Johnson, Charles C., Jr.—The Future of Consumer Protection. Dec., p. 608.

Jurow, Irving H. — Prescription-Drug Advertising—Blight or Light? May, p. 242.

K

Kegan, Esther O.—Federal Pre-emption in Consumer Laws. Feb., p. 79.

Kingsley, Robert — Legal Control of Narcotics. June, p. 306.

Kirk, Kenneth J. — Developments at FDA. Mar., p. 126.

Kleinfeld, Vincent A.

Industry and Government Cooperation—A Two-way Street. Sept., p. 444.

Kleinfeld, Vincent A.—continued
Prescription Drug Advertising and Labeling Regulations (The). Jan., p. 12.
Surgical Implants: Drugs or Devices, and New Device Legislation. Oct., p. 510.

L

Latin-American Food Code
Chapter IX. Nov., p. 550.
Chapter XI, Aug., p. 396.

Legal Aspects of Modified and Vegetable Fat Dairy Products. Apr., p. 209.

Legal Control of Narcotics. June, p. 306.

Levine, Selma M.—Separation of Functions in FDA Administrative Proceedings. Mar., p. 132.

Ley, Herbert L., Jr.—FDA Today and Tomorrow. Dec., p. 614.

Licenses
Search Warrants and Sanitation Inspections—The New Look in Enforcement. Feb., p. 52.
The EEC on the Way to a Common Market for Drugs: Its Meaning for Foreign Imports. Oct., p. 500.

M

Munsey, Rodney R.—Survey of Current Legal Problems in the Drug Area. Sept., p. 449.

N

Narcotics
Legal Control of Narcotics. June, p. 306.
Some Applications of Drug, Device and Narcotic Laws for Health Science Practitioners. Feb., p. 89.

Need for Formal GMP Guidelines in the Food Industry (The). Jan., p. 4.

Neighbor Comments Upon Some National and International Aspects of Food and Drug Legislation (A). Jan., p. 36.

Non-Prescription Drugs
The Right to Self-Medication—A Continuing Conflict Between Congressional and Agency Policy. Oct., p. 487.

O

Olszyna-Marzys, Andrzej E.—Food and Drug Legislation in Central America and Panama. May, p. 253.

Oser, Bernard L.
Current Tidings and Trends in Drug Appraisal. Jan., p. 42.
Where Is Industry's Voice in Food Regulations? June, p. 317.

P

Panama
Food and Drug Legislation in Central America and Panama. May, p. 253.

Pendergast, William R.—Have the FDA Hearing Regulations Failed Us? Nov., p. 524.

Pesticide Laws and Legal Implications of Pesticide Use (Part I). Mar., p. 142.

Pesticide Laws and Legal Implications of Pesticide Use (Part II). Apr., p. 172.

Pesticides
Petitions to establish tolerances or exemptions. Sept., p. 461.

Prescription-Drug Advertising—Blight or Light? May, p. 242.

Prescription Drug Advertising and Labeling Regulations (The). Jan., p. 12.

Prescription Drugs
Prescription - Drug Advertising — Blight or Light? May, p. 242.
The Prescription Drug Advertising and Labeling Regulations. Jan., p. 12.

Product Liability
In the use of pesticides. Apr., p. 172.
Product Liability—1967. Mar., p. 114.
Product Liability Cases for 1967. March, pp. 122-125.

Product Liability—1967. Mar., p. 114.

Q

Question and Answer Panel of the FDLI-FDA Eleventh Annual Educational Conference. Apr., p. 185.

Question and Answer Panel of the FDLI-FDA Eleventh Annual Educational Conference. July, p. 332.

Question and Answer Panel of the FDLI-FDA Eleventh Annual Educational Conference—Afternoon Session: Foods Workshop. July, p. 348.

R

Rankin, Winton B.—FDA Program for 1969 (The). Dec., p. 628.

Reasoned Approach to Regulation Based on Toxicologic Considerations (A). May, p. 260.

Regulation

A Reasoned Approach to Regulation Based on Toxicologic Considerations. May, p. 260.

Regulations

Drug Advertising Regulations. Jan., p. 21.

The Fair Packaging and Labeling Act—The Problems and Effects of Discretionary Regulations. Mar., p. 109.

The Prescription Drug Advertising and Labeling Regulations. Jan., p. 12.

Where Is Industry's Voice in Food Regulations? June, p. 317.

Regulator and the Regulated (The). Dec., p. 628.

Report of the Fifth Session of the Joint FAO/WHO Codex Alimentarius. May, p. 271.

Reports to the Reader. Jan., p. 3; Feb., p. 51; Mar., p. 107; Apr., p. 171; May, p. 235; June, p. 283; July, p. 331; Aug., p. 395; Sept., p. 443; Oct., p. 475; Nov., p. 523; Dec., p. 579.

Right to Self-Medication—A Continuing Conflict Between Congressional and Agency Policy (The). Oct., p. 487.

Risks v. Benefits in Cancer Drug Development. Jan., p. 29.

Risks v. Benefits in Drug Development. Jan., p. 25.

Rohrman, Douglass F.

Pesticide Laws and Legal Implications of Pesticide Use (Part I). Mar., p. 142.

Pesticide Laws and Legal Implications of Pesticide Use (Part II). Apr., p. 172.

S

Salmonellae

Question and Answer Panel of the FDLI-FDA Eleventh Annual Educational Conference. July, p. 348.

The Salmonellae—A Current Challenge. Mar., p. 164.

Salmonellae — A Current Challenge (The). Mar., p. 164.

Sampling and Testing of Drugs. Jan., p. 8.

Sampling and Testing of Drugs. Apr., p. 200.

Search Warrants

Constitutionality questioned in sanitation inspections. Feb., p. 52.

Search Warrants and Sanitation Inspections—The New Look in Enforcement. Feb., p. 52.

Self-Certification

The FDA Self-Certification Program. May, p. 236.

Self-Medication

The Right to Self-Medication—A Continuing Conflict Between Congressional and Agency Policy. Oct., p. 487.

Separation of Functions in FDA Administrative Proceedings. Mar., p. 132.

Smith, Austin—A View from the Top—The Pharmaceutical Manufacturer's Multi-Responsibilities. Apr., p. 203.

Some Applications of Drug, Device and Narcotic Laws for Health Science Practitioners. Feb., p. 89.

Some Common and Uncommon Hearing Procedures Under the Federal Food, Drug and Cosmetic Act. Sept., p. 457.

Some Suggestions for Improvements in the Hearing and Rulemaking Procedures of the Food and Drug Administration. Sept., p. 465.

Status of the Drug Efficacy Study of the National Academy of Sciences-National Research Council. Jan., p. 32.

Suerth, John C.—Welcoming Remarks. Dec., p. 604.

Surgical Implants

Definition of and standards for required. Oct., p. 510.

Surgical Implants: Drugs or Devices, and New Device Legislation. Oct., p. 510.

Survey of Current Legal Problems in the Drug Area. Sept., p. 449.

T

Tables

Analytical data of flours. Nov., p. 557.
Hearings at FDA since 1960. Nov., p. 526.
Laws of the several states governing use of pesticides. Mar., pp. 157-161.
Percentages of allocations to organizations for study of hazardous substances. Dec., p. 624.
Percentages of defective kernels in Carolina-type rices. Nov., p. 552.
Results of FDA tests for salmonellae. Mar., p. 168.

V

Vegetables

Fats of in dairy products. Apr., p. 209.
Latin-American Food Code—Chapter XI. Aug., p. 396.

View from the Top—The Pharmaceutical Manufacturer's Multi-Responsibilities (A). Apr., p. 203.

Voluntary Compliance

Current Good Manufacturing Practices Compliance—A Review of the Problems and an Approach to Their Management. Dec., p. 580.
Encouraged by bureau changes. Apr., p. 227.
Where Is Industry's Voice in Food Regulations? June, p. 317.

Voluntary Compliance Encouraged by Bureau Changes. Apr., p. 227.

W

Wartburg, von, Walter P.—The EEC on the Way to a Common Market for Drugs: Its Meaning for Foreign Imports. Oct., p. 500.

Welcoming Remarks. Dec., p. 604.

Where Is Industry's Voice in Food Regulations? June, p. 317.

Williams, Richard E.—Counsel's Role in Current Good Manufacturing Practice. Feb., p. 71.

Willig, Sidney H.
Ethical and Legal Implications of Drug Substitution. June, p. 284.
Some Applications of Drug, Device and Narcotic Laws for Health Science Practitioners. Feb., p. 89.

Y

Yakowitz, M. L.—Sampling and Testing of Drugs. Jan., p. 8.